Overview


Gastric motility disorders refer to conditions that affect the regular movement of the stomach muscles, which can lead to problems with digestion. These disorders can result in symptoms like abdominal pain, bloating, nausea, and changes in bowel habits. Several drugs are used in the management of gastric motility disorders. These medications aim to regulate food movement through the digestive tract, alleviate symptoms, and improve overall digestion. It's necessary to note that the choice of drug and its dosage will depend on the specific diagnosis, severity of symptoms, and individual patient factors.

Some commonly used drugs for gastric motility disorders are Velusetrag, Ipamorelin, TD-8954, and others. Velusetrag is a medication that belongs to the class of drugs known as serotonin (5-HT4) receptor agonists. It works by boosting serotonin receptors in the gut, which promotes gastrointestinal motility. This can be helpful in conditions where there are issues with gastric emptying, such as gastroparesis. Ipamorelin is a peptide drug that stimulates the release of growth hormone. While it's primarily used for its growth hormone-releasing properties, it may have secondary effects on gastrointestinal motility. However, it's not primarily indicated for gastric motility disorders. TD-8954 is a drug that acts as a selective 5-HT4 receptor agonist. Like velusetrag, it stimulates serotonin receptors in the gut, which can enhance gastrointestinal motility. It may be used in conditions where there are issues with gastric emptying.

FutureWise Market Research has published a report that provides an insightful analysis gastric motility disorder drug market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analyst’s gastric motility disorder drug market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbott
  • Janssen Pharmaceuticals NV
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Gilead Sciences, Inc.
  • Biogen
  • Organon Group of Companies 
  • AbbVie Inc.
  • AstraZeneca
  • Salix Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Bayer AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

The rising incidence of gastric motility disorders, such as gastroparesis, irritable bowel syndrome (IBS), and functional dyspepsia, may be primarily attributed to modern lifestyle factors. Sedentary routines, poor dietary habits, and increasing stress levels are key contributors. Prolonged hours of inactivity associated with unhealthy eating habits place significant strain on the digestive system, often resulting in these disorders. Additionally, boosted stress levels, a prevalent aspect of contemporary living, may significantly impact gastrointestinal function. Therefore, the influence of lifestyle factors emphasizes the crucial need for effective drugs targeting gastric motility disorders, thereby propelling growth in the market. Additionally, the development of innovative drug delivery systems and formulations revolutionized the treatment landscape of gastric motility disorders. These advancements have the potential to enhance drug effectiveness and patient convenience significantly. Tailored delivery mechanisms may ensure targeted and sustained release of medications, optimizing their absorption and therapeutic impact. Moreover, novel formulations offer more edible and easy-to-administer options, improving patient adherence to treatment approaches. By addressing key challenges in drug delivery, such innovations not only promise to advance treatment outcomes but also contribute to the overall growth and advancement of the gastric motility disorder drug market. However, the availability of alternative therapies, including dietary adjustments, lifestyle changes, and the embrace of complementary and alternative medicine (CAM) practices, impose a significant barrier to the pharmaceutical intervention market for gastric motility disorders. Patients seeking more holistic and non-pharmacological approaches may opt for these methods, potentially hampering the demand for traditional pharmaceutical treatments. Therefore, restraining the growth of the market.

By Type

  • Velusetrag
  • Ipamorelin
  • TD-8954
  • Others

By Application

  • Hospital
  • Clinic
  • Home Use

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to factors including the presence of gastric motility dysfunction, availability of medications for ulcerative colitis, rising product approvals, the presence of numerous market players, the rising frequency of diseases, and the existence of numerous government and non-government organizations to support research initiatives for drugs for gastric motility disorders are boosting the growth of gastric motility disorder drug market's expansion. Moreover, with the high prevalence of chronic diseases, rising healthcare infrastructure, research and development efforts, rising demand for new-generation pharmaceuticals, and the accessibility of advanced treatment choices, the region is expected to maintain its dominance over the projected period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Gastric Motility Disorder Drug Market By Type, By Application, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction

    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology

    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary

    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Gastric Motility Disorder Drug Market Variables, Trends & Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview

    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Gastric Motility Disorder Drug Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Gastric Motility Disorder Drug Market Analysis Tools

    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Gastric Motility Disorder Drug Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Velusetrag
        2. Ipamorelin
        3. Industry Value Chain Analysis
        4. TD-8954
        5. Others

  • 8.  Gastric Motility Disorder Drug Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Hospital
        2. Clinic
        3. Home Use

  • 9.  North America Gastric Motility Disorder Drug Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.  Latin America Gastric Motility Disorder Drug Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.  Europe Gastric Motility Disorder Drug Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.  Asia Pacific Gastric Motility Disorder Drug Market Analysis 2024-2032 and Forecast 2018-2023 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2024-2032
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2018-2023 

  • 13.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Abbott
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Janssen Pharmaceuticals NV
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Sun Pharmaceutical Industries Ltd.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Cipla Inc.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Gilead Sciences, Inc.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Biogen
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Organon Group of Companies 
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. AbbVie Inc.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. AstraZeneca
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Salix Pharmaceuticals
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Takeda Pharmaceutical Company Limited
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Pfizer Inc.
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Bayer AG
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated
      by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11